NMIBC
Clinical trials for NMIBC explained in plain language.
Never miss a new study
Get alerted when new NMIBC trials appear
Sign up with your email to follow new studies for NMIBC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a Bladder-Instilled biologic keep recurrent bladder cancer at bay?
Disease control Not yet recruitingThis early-phase trial is testing a new biologic drug, UGN-501, for people whose non-muscle invasive bladder cancer has returned after previous treatment. The drug is given directly into the bladder through a catheter once a week for six weeks, with possible quarterly maintenance…
Matched conditions: NMIBC
Phase: PHASE1 • Sponsor: UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New biologic combo aims to spare bladders in cancer fight
Disease control Not yet recruitingThis early-phase trial tests a new biologic drug called SPGL008, given alone or with the standard therapy BCG, in 120 people with high-risk non-muscle-invasive bladder cancer who are not candidates for bladder removal. The main goals are to find a safe dose and see if the drug ca…
Matched conditions: NMIBC
Phase: PHASE1, PHASE2 • Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC